Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Consumer Services and Consumer Goods sectors led shares higher. At the close in...
Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Utilities, Industrials and Consumer Services sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Oil & Gas, Financials and Consumer Goods sectors led shares higher. At the close in NYSE, the...
Investors always look for stocks with low P/E ratios as the measure indicates undervaluation. This ratio is obtained by dividing a stock’s current market price with its...
We are initiating research on Jaguar Health Inc (NASDAQ:JAGX), which is centered on the development and marketing of its drug crofelemer for diarrheal disorders. It is approved and...
On Thursday, shares of animal health company Jaguar Animal Health Inc. (NASDAQ:JAGX) are skyrocketing, up 115% in morning trading after the company announced it has entered into...
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 138.23 | 141.11 | 137.91 | -4.07 | -2.86% | 46.92M | NASDAQ | |||
| 49.15 | 49.44 | 48.73 | +0.57 | +1.17% | 15.25M | NYSE | |||
| 463.95 | 470.76 | 459.77 | -13.81 | -2.89% | 1.50M | NASDAQ | |||
| 11.03 | 12.55 | 10.26 | -7.52 | -40.54% | 132.61M | NASDAQ | |||
| 89.63 | 91.65 | 89.18 | -1.11 | -1.22% | 10.81M | NYSE | |||
| 18.70 | 18.98 | 18.07 | +0.14 | +0.75% | 21.88K | NASDAQ | |||
| 266.54 | 267.75 | 265.54 | -0.04 | -0.01% | 1.76M | NYSE | |||
| 1.80 | 1.918 | 1.78 | -0.090 | -4.76% | 1.08M | NASDAQ | |||
| 0.97 | 0.995 | 0.948 | +0.030 | +3.17% | 6.34K | NASDAQ | |||
| 1.66 | 1.87 | 1.51 | -0.21 | -11.23% | 352.60K | NASDAQ | |||
| 183.77 | 185.44 | 181.58 | -4.16 | -2.21% | 4.24M | NYSE | |||
| 7.57 | 8.06 | 7.54 | -0.59 | -7.23% | 1.11M | NASDAQ | |||
| 5.14 | 5.219 | 5.14 | -0.070 | -1.34% | 47.26K | NYSE | |||
| 71.29 | 72.49 | 63.84 | +6.41 | +9.88% | 79.50M | NYSE | |||
| 713.85 | 737.25 | 712.31 | -31.37 | -4.21% | 770.23K | NYSE |